Hirvasniemi, Jukka
Thevenot, Jérôme
Guermazi, Ali
Podlipská, Jana
Roemer, Frank W.
Nieminen, Miika T.
Saarakkala, Simo
Article History
Received: 3 October 2016
Revised: 13 March 2017
Accepted: 20 March 2017
First Online: 24 April 2017
Compliance with ethical standards
:
: The scientific guarantor of this publication is Simo Saarakkala.
: The authors of this manuscript declare relationships with the following companies: Ali Guermazi is the President of Boston Imaging Core Lab (BICL), LLC and a consultant to MerckSerono, Genzyme, OrthoTrophix and TissueGene. Frank W Roemer is the CMO and a shareholder of BICL. The other authors declare that they have no competing interests.
: This study has received funding by the Radiological Society of Finland, the Orion Corporation Research Foundation, Päivikki and Sakari Sohlberg Foundation, Academy of Finland (project 268378), University of Oulu (strategic funding), Sigrid Juselius Foundation, and European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 336267. The funding sources had no role in the study design, data collection or analysis, interpretation of data, writing of the manuscript, or in the decision to submit the manuscript for publication.
: Marianne Haapea, Ph.D. kindly provided statistical advice for this manuscript.
: Institutional review board approval was obtained.
: Written informed consent was obtained from all subjects (patients) in this study.
: The study subjects have been previously reported in Scientific Reports by Podlipská et al. 2016 [CitationRef removed].
: • retrospective• cross sectional study• performed at one institution